4.5 Article

Abrogation of LRRK2 dependent Rab10 phosphorylation with TLR4 activation and alterations in evoked cytokine release in immune cells

Journal

NEUROCHEMISTRY INTERNATIONAL
Volume 147, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuint.2021.105070

Keywords

LRRK2 phosphorylation; RAW264; 7; LPS; Zymosan; Rab10 phosphorylation; MAPK; TAK242; Sparstolonin B; Cytokine release; IPS-Macrophage

Funding

  1. Reta Lila Weston Trust for Neurological disorders (UCL)
  2. Alzheimer's Society Junior Fellowship [AS-JF-18-008]
  3. Medical Research Council [MR/N026004/1]
  4. Michael J. Fox Foundation for Parkinson's research [18285]
  5. UK Dementia Research Institute from DRI Ltd - UK Medical Research Council
  6. Alzheimer's Society
  7. Alzheimer's Research UK
  8. Wellcome Trust Hardy [202903/Z/16/Z]
  9. Dolby Family Fund
  10. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  11. BRCNIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust
  12. University College London
  13. Innovative Medicines Initiative 2 Joint Undertaking grant [115976]
  14. European Union's Horizon 2020 research and innovation program
  15. EFPIA
  16. MRC [UKDRI-1009] Funding Source: UKRI

Ask authors/readers for more resources

Our study revealed that LRRK2-dependent Rab10 phosphorylation is modulated by LPS stimulation, and cytokine release may be influenced by the status of LRRK2. This provides new insights into the immune response function of LRRK2.
LRRK2 protein is expressed prominently in immune cells, cell types whose contribution to LRRK2-associated genetic Parkinson's disease (PD) is increasingly being recognised. We investigated the effect of inflammatory stimuli using RAW264.7 murine macrophage cells as model systems. A detailed time course of TLR2 and TLR4 stimulation was investigated through measuring LRRK2 phosphorylation at its specific phospho-sites, and Rab8 and Rab10 phosphorylation together with cytokine release following treatment with LPS and zymosan. LRRK2 phosphorylation at Ser935, Ser955 and Ser973 was increased significantly over untreated conditions at 4-24h in both WT-LRRK2 and T1348N-LRRK2 cell lines to similar extents although levels of Ser910 phosphorylation were maintained at higher levels throughout. Importantly we demonstrate that LPS stimulation significantly decreased phospho-Rab10 but not phospho-Rab8 levels over 4-24h in both WT-LRRK2 and T1348N-LRRK2 cell lines. The dephosphorylation of Rab10 was not attributed to its specific phosphatase, PPM1H as the levels remained unaltered with LPS treatment. MAPK phosphorylation occurred prior to LRRK2 phosphorylation which was validated by blocking TLR4 and TLR2 receptors with TAK242 or Sparstolonin B respectively. A significant decrease in basal level of TNF alpha release was noted in both T1348N-LRRK2 and KO-LRRK2 cell lines at 48h compared to WT-LRRK2 cell line, however LPS and zymosan treatment did not cause any significant alteration in the TNF alpha and IL-6 release between the three cell lines. In contrast, LPS and zymosan caused significantly lower IL-10 release in T1348N-LRRK2 and KO-LRRK2 cell lines. A significant decrease in phospho-Rab10 levels was also confirmed in human IPS-derived macrophages with TLR4 activation. Our data demonstrates for the first time that LRRK2-dependent Rab10 phosphorylation is modulated by LPS stimulation, and that cytokine release may be influenced by the status of LRRK2. These data provide further insights into the function of LRRK2 in immune response, and has relevance for understanding cellular dysfunctions when developing LRRK2-based inhibitors for clinical treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available